Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Reports Increased Revenues in Q4

NEW YORK, Jan. 28 (GenomeWeb News) – PerkinElmer today reported revenues of $432.6 million for the fourth quarter ended Dec. 28, 2003, up from $410 million for the same period in 2002.

The increase, which included a 6 percent boost from foreign currency exchange rate fluctuations, was driven by revenue growth in all segments, the company said in a statement.

The company had net income of $28 million for the quarter, compared to a loss of $2.6 million for the year-ago quarter. The company had net income of $52 million for the year, compared to a loss of $152 million for 2002.

PerkinElmer had research and development expenditures of $20 million for the fourth quarter, compared to $22 million for the year-ago period.

Cash and cash equivalents on hand at the end of the quarter totaled $191 million, compared to $131 million for the same period in 2002.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more